Leukopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major leukopenia markets reached a value of US$ 10.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 16.5 Billion by 2034, exhibiting a growth rate (CAGR) of 4.53% during 2024-2034.
The leukopenia market has been comprehensively analyzed in IMARC's new report titled "Leukopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leukopenia is a medical condition characterized by a lower-than-normal white blood cell count in the bloodstream. These cells play a crucial role in the immune system, defending the body against infections and diseases. When the white blood cell level drops below the normal range, which is typically around 4,000 to 11,000 cells per microliter of blood, the body's ability to fight off infections becomes compromised. The symptoms of leukopenia can vary based on the severity of the illness and the underlying cause. Common indications include increased susceptibility to infections, frequent fevers, fatigue, and overall weakness. In more severe cases, patients might experience mouth sores and persistent infections that are challenging to treat. Diagnosing leukopenia involves a blood workup known as a complete blood count (CBC). This test measures the levels of various blood components, including white blood cells. A substantially lower white blood cell count than the normal range confirms the diagnosis.
The increasing prevalence of certain disorders affecting the bone marrow, including aplastic anemia and myelodysplastic syndromes that can lead to decreased production of white blood cells, is primarily driving the leukopenia market. In addition to this, the inflating utilization of impactful treatments, such as colony-stimulating factors, corticosteroids, and immune-modulating drugs to manage the condition and alleviate its adverse effects among patients is also creating a positive outlook for the market. Moreover, the widespread adoption of infection prevention measures and lifestyle adjustments, as they play a pivotal role in maintaining white blood cell counts and overall health, is further propelling the market growth. Apart from this, the rising usage of innovative therapies like stem cell transplants, since they involve replenishing the bone marrow with healthy stem cells to enhance the formation of white blood cells, is acting as another significant growth-inducing factor. Additionally, the emerging advancements in medical technologies, such as machine learning algorithms for predictive diagnosis and treatment outcomes, are also augmenting the market growth. Furthermore, the escalating application of gene therapy techniques, where functional genes are introduced to replace or rectify the malfunctioning genes causing the condition, is expected to drive the leukopenia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the leukopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leukopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leukopenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the leukopenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the leukopenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current leukopenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the leukopenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the leukopenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the leukopenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of leukopenia across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukopenia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukopenia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with leukopenia across the seven major markets?
What is the size of the leukopenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of leukopenia?
What will be the growth rate of patients across the seven major markets?
Leukopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for leukopenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leukopenia market?
What are the key regulatory events related to the leukopenia market?
What is the structure of clinical trial landscape by status related to the leukopenia market?
What is the structure of clinical trial landscape by phase related to the leukopenia market?
What is the structure of clinical trial landscape by route of administration related to the leukopenia market?
The leukopenia market has been comprehensively analyzed in IMARC's new report titled "Leukopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leukopenia is a medical condition characterized by a lower-than-normal white blood cell count in the bloodstream. These cells play a crucial role in the immune system, defending the body against infections and diseases. When the white blood cell level drops below the normal range, which is typically around 4,000 to 11,000 cells per microliter of blood, the body's ability to fight off infections becomes compromised. The symptoms of leukopenia can vary based on the severity of the illness and the underlying cause. Common indications include increased susceptibility to infections, frequent fevers, fatigue, and overall weakness. In more severe cases, patients might experience mouth sores and persistent infections that are challenging to treat. Diagnosing leukopenia involves a blood workup known as a complete blood count (CBC). This test measures the levels of various blood components, including white blood cells. A substantially lower white blood cell count than the normal range confirms the diagnosis.
The increasing prevalence of certain disorders affecting the bone marrow, including aplastic anemia and myelodysplastic syndromes that can lead to decreased production of white blood cells, is primarily driving the leukopenia market. In addition to this, the inflating utilization of impactful treatments, such as colony-stimulating factors, corticosteroids, and immune-modulating drugs to manage the condition and alleviate its adverse effects among patients is also creating a positive outlook for the market. Moreover, the widespread adoption of infection prevention measures and lifestyle adjustments, as they play a pivotal role in maintaining white blood cell counts and overall health, is further propelling the market growth. Apart from this, the rising usage of innovative therapies like stem cell transplants, since they involve replenishing the bone marrow with healthy stem cells to enhance the formation of white blood cells, is acting as another significant growth-inducing factor. Additionally, the emerging advancements in medical technologies, such as machine learning algorithms for predictive diagnosis and treatment outcomes, are also augmenting the market growth. Furthermore, the escalating application of gene therapy techniques, where functional genes are introduced to replace or rectify the malfunctioning genes causing the condition, is expected to drive the leukopenia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the leukopenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leukopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leukopenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the leukopenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the leukopenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current leukopenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the leukopenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the leukopenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the leukopenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of leukopenia across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukopenia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of leukopenia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with leukopenia across the seven major markets?
What is the size of the leukopenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of leukopenia?
What will be the growth rate of patients across the seven major markets?
Leukopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for leukopenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leukopenia market?
What are the key regulatory events related to the leukopenia market?
What is the structure of clinical trial landscape by status related to the leukopenia market?
What is the structure of clinical trial landscape by phase related to the leukopenia market?
What is the structure of clinical trial landscape by route of administration related to the leukopenia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LEUKOPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (2024-2034)
4.4 Market Overview (?2018-2023?) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LEUKOPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LEUKOPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034)
7.2.4 Epidemiology by Gender (?2018-2034)
7.2.5 Diagnosed Cases (?2018-2034)
7.2.6 Patient Pool/Treated Cases (?2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034)
7.3.4 Epidemiology by Gender (?2018-2034)
7.3.5 Diagnosed Cases (?2018-2034)
7.3.6 Patient Pool/Treated Cases (?2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034)
7.4.4 Epidemiology by Gender (?2018-2034)
7.4.5 Diagnosed Cases (?2018-2034)
7.4.6 Patient Pool/Treated Cases (?2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034)
7.5.4 Epidemiology by Gender (?2018-2034)
7.5.5 Diagnosed Cases (?2018-2034)
7.5.6 Patient Pool/Treated Cases (?2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034)
7.6.4 Epidemiology by Gender (?2018-2034)
7.6.5 Diagnosed Cases (?2018-2034)
7.6.6 Patient Pool/Treated Cases (?2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034)
7.7.4 Epidemiology by Gender (?2018-2034)
7.7.5 Diagnosed Cases (?2018-2034)
7.7.6 Patient Pool/Treated Cases (?2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034)
7.8.4 Epidemiology by Gender (?2018-2034)
7.8.5 Diagnosed Cases (?2018-2034)
7.8.6 Patient Pool/Treated Cases (?2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034)
7.9.4 Epidemiology by Gender (?2018-2034)
7.9.5 Diagnosed Cases (?2018-2034)
7.9.6 Patient Pool/Treated Cases (?2018-2034)
8 LEUKOPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LEUKOPENIA - UNMET NEEDS
10 LEUKOPENIA - KEY ENDPOINTS OF TREATMENT
11 LEUKOPENIA - MARKETED PRODUCTS
11.1 List of Leukopenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zarxio (Filgrastim biosimilar) - Sandoz
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LEUKOPENIA - PIPELINE DRUGS
12.1 List of Leukopenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Mavorixafor - X4 Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 LEUKOPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 LEUKOPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LEUKOPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Leukopenia - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Leukopenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Leukopenia - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Leukopenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Leukopenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Leukopenia - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Leukopenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Leukopenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Leukopenia - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Leukopenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Leukopenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Leukopenia - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Leukopenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Leukopenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Leukopenia - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Leukopenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Leukopenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Leukopenia - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Leukopenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Leukopenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Leukopenia - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Leukopenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Leukopenia - Access and Reimbursement Overview
16 LEUKOPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LEUKOPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LEUKOPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LEUKOPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (2024-2034)
4.4 Market Overview (?2018-2023?) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LEUKOPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LEUKOPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034)
7.2.4 Epidemiology by Gender (?2018-2034)
7.2.5 Diagnosed Cases (?2018-2034)
7.2.6 Patient Pool/Treated Cases (?2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034)
7.3.4 Epidemiology by Gender (?2018-2034)
7.3.5 Diagnosed Cases (?2018-2034)
7.3.6 Patient Pool/Treated Cases (?2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034)
7.4.4 Epidemiology by Gender (?2018-2034)
7.4.5 Diagnosed Cases (?2018-2034)
7.4.6 Patient Pool/Treated Cases (?2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034)
7.5.4 Epidemiology by Gender (?2018-2034)
7.5.5 Diagnosed Cases (?2018-2034)
7.5.6 Patient Pool/Treated Cases (?2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034)
7.6.4 Epidemiology by Gender (?2018-2034)
7.6.5 Diagnosed Cases (?2018-2034)
7.6.6 Patient Pool/Treated Cases (?2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034)
7.7.4 Epidemiology by Gender (?2018-2034)
7.7.5 Diagnosed Cases (?2018-2034)
7.7.6 Patient Pool/Treated Cases (?2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034)
7.8.4 Epidemiology by Gender (?2018-2034)
7.8.5 Diagnosed Cases (?2018-2034)
7.8.6 Patient Pool/Treated Cases (?2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034)
7.9.4 Epidemiology by Gender (?2018-2034)
7.9.5 Diagnosed Cases (?2018-2034)
7.9.6 Patient Pool/Treated Cases (?2018-2034)
8 LEUKOPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LEUKOPENIA - UNMET NEEDS
10 LEUKOPENIA - KEY ENDPOINTS OF TREATMENT
11 LEUKOPENIA - MARKETED PRODUCTS
11.1 List of Leukopenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Zarxio (Filgrastim biosimilar) - Sandoz
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LEUKOPENIA - PIPELINE DRUGS
12.1 List of Leukopenia Pipeline Drugs Across the Top 7 Markets
12.1.1 Mavorixafor - X4 Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 LEUKOPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 LEUKOPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LEUKOPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Leukopenia - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Leukopenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Leukopenia - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Leukopenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Leukopenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Leukopenia - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Leukopenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Leukopenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Leukopenia - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Leukopenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Leukopenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Leukopenia - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Leukopenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Leukopenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Leukopenia - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Leukopenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Leukopenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Leukopenia - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Leukopenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Leukopenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Leukopenia - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Leukopenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Leukopenia - Access and Reimbursement Overview
16 LEUKOPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LEUKOPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LEUKOPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
